Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics

BACKGROUND: Poly (ADP)-ribose polymerase (PARP) inhibitors have entered routine clinical practice for the treatment of high-grade serous ovarian cancer (HGSOC), yet the molecular mechanisms underlying treatment response to PARP1 inhibition (PARP1i) are not fully understood. METHODS: Here, we used un...

Descripción completa

Detalles Bibliográficos
Autores principales: Franz, Alexandra, Coscia, Fabian, Shen, Ciyue, Charaoui, Lea, Mann, Matthias, Sander, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539835/
https://www.ncbi.nlm.nih.gov/pubmed/34686201
http://dx.doi.org/10.1186/s13048-021-00886-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539835/
https://www.ncbi.nlm.nih.gov/pubmed/34686201
http://dx.doi.org/10.1186/s13048-021-00886-x

Ejemplares similares